BioNTech, Fosun Pharma Expected to Supply 10 Million COVID-19 Vaccine Doses in China

BioNTech and Fosun Pharma have announced the first COVID-19 supply deal in China for up to 10 million doses of their mRNA-based vaccine.

China-based Fosun signed a letter of intent with Hong Kong-based drugmaker Jacobson Pharma yesterday for the doses to be distributed to Hong Kong and Macau. Terms of the deal were not disclosed, and BioNTech was not part of the letter of intent.

BioNTech and Fosun Pharma began working together in March to develop and commercialize their vaccine in China. A phase 1 trial of their vaccine candidate BNT162b1 was launched in China earlier this month. — Jordan Williams